title: Targeted therapy of human immunodeficiency virus-related disease.
abstract: Since the discovery of human immunodeficiency virus (HIV) as a pathogenic retrovirus linked to acquired immunodeficiency syndrome (AIDS), a number of potentially useful strategies for antiretroviral therapy of AIDS and its related diseases have emerged. One such strategy involves use of the broad family of 2',3'-dideoxynucleosides, to which 3'-azido-2',3'-dideoxythymidine (AZT) belongs. AZT has been shown to reduce the replication of HIV in vivo and to confer significant clinical benefits in patients in both early and advanced stages of infection. Other members of the family, 2',3'-dideoxycytidine (ddC), 2',3'-dideoxyinosine (ddI), and 2',3'-didehydro-2',3'-dideoxythymidine (d4T), have also been reported to be active against HIV in short-term clinical trials. The armamentarium of antiretroviral agents is rapidly growing. Various nonnucleoside agents have recently been identified to be active against HIV in vitro. HIV-1 protease inhibitors are notable as possible new therapies for HIV-1-related diseases. However, we have faced several new challenges in the antiretroviral therapy in AIDS. These include long-term drug-related toxicities; emergence of drug-resistant HIV variants; and development of various cancers, particularly as effective therapies prolong survival. Progress in understanding structure-activity relations and clinical effectiveness will continue with dideoxynucleoside analogs. However, it seems certain that a variety of nonnucleoside analogs affecting multiple steps in viral replication will become available before long, and combination therapies using multiple antiretroviral drugs will be available. Such therapies will exert major effects against the moribidity and mortality caused by HIV.
authors.affiliation: Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
authors.forename: H
authors.initials: H
authors.lastname: Mitsuya
authors.forename: R
authors.initials: R
authors.lastname: Yarchoan
authors.forename: S
authors.initials: S
authors.lastname: Kageyama
authors.forename: S
authors.initials: S
authors.lastname: Broder
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology; D015704:CD4 Antigens / Q000627:therapeutic use; D016049:Didanosine / Q000009:adverse effects / Q000494:pharmacology; D015224:Dideoxynucleosides / Q000009:adverse effects / Q000494:pharmacology; D004176:Dipyridamole / Q000627:therapeutic use; D004357:Drug Synergism; D015967:Gene Expression Regulation, Viral / Q000187:drug effects*; D015754:Genes, nef / Q000502:physiology; D015757:Genes, rev / Q000502:physiology; D015756:Genes, tat / Q000502:physiology; D006678:HIV / Q000187:drug effects / Q000472:pathogenicity; D016333:HIV Protease / Q000187:drug effects; D007370:Interferon Type I / Q000627:therapeutic use; D063065:Organophosphonates; D012194:RNA-Directed DNA Polymerase / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D018119:Stavudine; D014158:Transcription, Genetic / Q000187:drug effects; D016047:Zalcitabine / Q000494:pharmacology; D015215:Zidovudine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D015704:CD4 Antigens; D015224:Dideoxynucleosides; D007370:Interferon Type I; D063065:Organophosphonates; D015215:Zidovudine; D004176:Dipyridamole; C053001:adefovir; D016047:Zalcitabine; D018119:Stavudine; D012194:RNA-Directed DNA Polymerase; D016333:HIV Protease; D000225:Adenine; D016049:Didanosine; C058803:3'-azido-2',3'-dideoxyuridine